Bruker Sells GC Business
News Nov 04, 2014
Techcomp intends to continue to manufacture the former Bruker GC and GC-SQ SCION™ products in the Fremont, CA, factory previously occupied by Bruker’s Chemical and Applied Markets (CAM) division.
Selected Bruker CAM GC and GC-SQ sales, marketing, applications and operations employees are expected to be offered positions with Techcomp. Bruker will continue to provide service and support for all GC and GC-SQ products worldwide. As part of the transaction, Techcomp has a deferred option to acquire the service business for GC and GC-SQ products in the next twelve months.
The GC product line divestiture is an important part of Bruker’s restructuring of its CAM division, which was announced in July 2014. In September 2014, Bruker’s CAM division already had divested its Inductively-Coupled Plasma Mass Spectrometry (ICP-MS) product line and service business to Analytik Jena AG.
In addition, Bruker is in the process of relocating the manufacturing of its GC triple-quadrupole and LC triple-quadrupole (GC-TQ and LC-TQ) mass spectrometers from Fremont, CA to Bremen, Germany, with GC-TQ and LC-TQ product research and development being transferred to Bruker’s major mass spectrometry sites in Bremen and Billerica, MA. Bruker will continue to service and support its GC-TQ and LC-TQ products indefinitely. The Bruker-internal transfer of its GC-TQ and LC-TQ business is expected to be finalized in the first half of 2015.
Arrow Poison Potential Male Birth ControlNews
Women have many options for oral contraceptives that are safe, effective and reversible, but despite decades of research, men have none. Now, scientists report a rat study that shows they finally have a good lead for a male birth control pill. It's based on ouabain, a plant extract that African warriors and hunters traditionally used as a heart-stopping poison on their arrows.READ MORE
Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule InhibitorsNews
A new original research article presents a fast, sensitive, and robust methodology for screening small molecule inhibitors against CD73/Ecto-5'-Nucleotidase, a promising target for developing anti-cancer drugs.READ MORE